This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.
Revlimid (lenalidomide). Myeloma. Eisai. Halaven (eribulin). Breast cancer. Gilead Sciences. Zydelig (idelalisib).
Zydelig (idelalisib) has been approved by the European Commission for use in the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL).
Just last week the European Medicines Agency (EMA) issued recommendations to both Janssen's Imbruvica (ibrutinib) and Gilead's Zydelig (idelalisib) in CLL indications.
Genmab's Arzerra (ofatumumab) in April 2014 and Gilead Science's Zydelig (idelalisib) just this month.
The recommendation for Gilead's Zydelig (idelalisib) covers its use in the treatment of patients with chronic lymphocytic leukaemia and patients with refractory follicular lymphoma.
The FDA recommended the use of Zydelig (idelalisib) in combination with Roche's Rituxan (rituximab) to treat patients with relapsed chronic lymphocytic leukaemia.
More from news
Approximately 2 fully matching, plus 12 partially matching documents found.